Skip to main content

VYNDAMAX

VYNDAMAX PAP

User account menu

Log in

Breadcrumb

Home
Contact Us

Contact us

VYNDAMAX Patient Assistance Program (PAP)

Phone:: 1800 896 629 (1800 VYNMAX)

Email:: [email protected]

Footer menu

HOME
PRODUCT INFORMATION
TERMS OF USE
PRIVACY POLICY
CONTACT US
PFIZER AUSTRALIA

PBS information: Authority required. Refer to the PBS Schedule for full authority information.

Before prescribing, please review Product Information available from here.

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

To monitor outcomes of pregnant women exposed to VYNDAMAX, a Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO) program has been established. If a pregnancy occurs in a woman being treated with VYNDAMAX, medical or healthcare professionals are encouraged to report the pregnancy to Pfizer Australia.

©2023 Pfizer Australia Pty Ltd. ABN 50 008 422 348. Sydney, Australia. Medical Information: 1800 675 229.
^®Registered trademark. Date of preparation: May 2024. PP-VDM-AUS-0216 Zest/PFISY1772